Mass production of full-length IgG monoclonal antibodies from mammalian, yeast, and bacterial hosts

Sang T. Jung, Dong Il Kim

Research output: Chapter in Book/Report/Conference proceedingChapter


IgG antibodies are tetramers formed by the assembly of two identical heavy chains and two light chains and are critical modulators of various immune responses. This chapter discusses follow-on biosimilar mAbs that are biologically equivalent to the original commercialized ones, summarize current biopharmaceutical processes for the mass production oftherapeutic antibodies using well-established mammalian cell culture systems, and discuss analytical methods for evaluating the physicochemical or functional quality of the follow-on mAb therapeutics. It highlights recently developed breakthrough technologies that employ microbial expression systems that have overcome the limitations of current mammalian cell culture systems and have allowed simple and cheap production of therapeutic mAbs. Yeast is a eukaryote that possesses cellular glycosylation machinery. The fast growth of bacterial cells allows for rapid production of mAbs. Compared with mammalian cell culture systems, development of prokaryotic cell lines requires much less time.

Original languageEnglish
Title of host publicationEmerging Areas in Bioengineering
Number of pages17
ISBN (Electronic)9783527803286
ISBN (Print)9783527340880
Publication statusPublished - 2017 Jan 1
Externally publishedYes


  • Bacterial cells
  • Cellular glycosylation machinery
  • IgG antibodies
  • Mammalian cell culture systems
  • Microbial expression systems
  • Therapeutic mAb
  • Yeast

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Mass production of full-length IgG monoclonal antibodies from mammalian, yeast, and bacterial hosts'. Together they form a unique fingerprint.

Cite this